Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 SAD/MAD Study of JNJ-64264681 in Healthy Subjects
NCT03607513Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2018
- Primary completion
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of JNJ-64264681 in B cell malignancies (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Number of Participants with Adverse Events, Maximum Observed Plasma Concentration and 4 more. Started Jul 2018; status: completed.
02
Drugs
JNJ-64264681
03
Conditions
B cell malignancies
Beyond the preview
Go deeper on NCT03607513.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03607513.